GLYLINA D

GLYLINA-D by Voithea Healthcare is a powerful anti-diabetic formulation that combines Linagliptin 5mg and Dapagliflozin 10mg. This dual-action therapy offers comprehensive glycemic control by addressing multiple pathways: enhancing incretin activity to increase insulin secretion and reduce glucagon levels, while also promoting glucose excretion through the kidneys.

Specially designed for patients with type 2 diabetes, GLYLINA-D not only helps in reducing blood sugar levels effectively but also supports cardiovascular and renal health. With its complementary mechanisms, GLYLINA-D represents Voithea Healthcare’s commitment to innovative, patient-focused diabetic management.